|Previous Section||Index||Home Page|
Mr. Hutton [pursuant to his reply, 24 May 2004, Official Report, c. 1389W]: I regret my previous response was incorrect, due to an error in the published figures. The correct figures are shown in the table.
|Patients of UPEs||309,365|
|Average list size||1,778|
(2) what guidance is given to local health trusts and local health boards about the availability of teriparatide on the NHS. 
Dr. Ladyman: Teriparatide is being considered as part of the National Institute for Clinical Excellence's (NICE's) appraisal of the clinical effectiveness and cost effectiveness of technologies for the secondary prevention of osteoporotic fractures in postmenopausal women. NICE has developed guidance in consultation with a number of stakeholders. Final guidance was due to be published in October 2004, covering both England and Wales, but an appeal has been received against the final appraisal determination and guidance on this technology. NICE has arranged for the appeal panel to convene on 22 October 2004 to hear oral representations from the appellant. Full details are available on the NICE website at www.nice.org.uk.
In August 1999, the Department issued Health Service Circular 1999/176, which asks national health service bodies to continue with local arrangements for the managed introduction of new technologies where guidance from NICE is not available at the time the technology first became available. These arrangements should involve an assessment of all the available evidence. The circular applies to England only.